Jasper Ridge Partners L.P. Acquires New Stake in Iqvia Holdings Inc (IQV)

Jasper Ridge Partners L.P. acquired a new position in Iqvia Holdings Inc (NYSE:IQV) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 2,459 shares of the medical research company’s stock, valued at approximately $319,000.

Other hedge funds also recently bought and sold shares of the company. Cornerstone Wealth Management LLC bought a new position in Iqvia during the second quarter valued at approximately $176,000. Piedmont Investment Advisors LLC bought a new position in Iqvia during the second quarter valued at approximately $189,000. Aperio Group LLC grew its holdings in shares of Iqvia by 2.8% in the second quarter. Aperio Group LLC now owns 87,810 shares of the medical research company’s stock worth $8,765,000 after purchasing an additional 2,358 shares during the last quarter. Raymond James Financial Services Advisors Inc. grew its holdings in shares of Iqvia by 13.2% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 138,459 shares of the medical research company’s stock worth $13,821,000 after purchasing an additional 16,140 shares during the last quarter. Finally, TD Asset Management Inc. grew its holdings in shares of Iqvia by 1.7% in the second quarter. TD Asset Management Inc. now owns 129,588 shares of the medical research company’s stock worth $12,936,000 after purchasing an additional 2,190 shares during the last quarter. Institutional investors own 89.33% of the company’s stock.

IQV has been the subject of a number of research analyst reports. Robert W. Baird raised their price target on Iqvia from $143.00 to $146.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 2nd. Royal Bank of Canada raised their price target on Iqvia to $137.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 23rd. Raymond James raised their price target on Iqvia from $136.00 to $145.00 and gave the stock a “strong-buy” rating in a research note on Friday, August 31st. Barclays raised their price target on Iqvia from $130.00 to $140.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 23rd. Finally, Zacks Investment Research lowered Iqvia from a “buy” rating to a “hold” rating in a research note on Monday, August 20th. Five equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $134.41.

Iqvia stock opened at $125.07 on Monday. The stock has a market cap of $25.30 billion, a price-to-earnings ratio of 28.69, a PEG ratio of 1.79 and a beta of 0.81. Iqvia Holdings Inc has a 52-week low of $91.57 and a 52-week high of $135.48. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 1.41.

Iqvia (NYSE:IQV) last released its quarterly earnings results on Monday, October 22nd. The medical research company reported $1.42 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.39 by $0.03. The business had revenue of $2.59 billion during the quarter, compared to the consensus estimate of $2.58 billion. Iqvia had a return on equity of 13.69% and a net margin of 12.29%. Iqvia’s quarterly revenue was up 5.2% on a year-over-year basis. On average, sell-side analysts expect that Iqvia Holdings Inc will post 5.13 earnings per share for the current fiscal year.

In other news, Director John G. Danhakl sold 370,470 shares of the company’s stock in a transaction that occurred on Wednesday, September 12th. The stock was sold at an average price of $124.83, for a total transaction of $46,245,770.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Kevin C. Knightly sold 9,216 shares of the company’s stock in a transaction that occurred on Friday, September 7th. The stock was sold at an average price of $126.46, for a total value of $1,165,455.36. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 601,586 shares of company stock valued at $75,510,422. Corporate insiders own 6.00% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.com-unik.info/2018/12/03/jasper-ridge-partners-l-p-acquires-new-stake-in-iqvia-holdings-inc-iqv.html.

Iqvia Company Profile

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Featured Story: Understanding Average Daily Trade Volume

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit